Lycopene inhibits lymphocyte proliferation through mechanisms dependent on early cell activation.
Epidemiological evidence suggests that lycopene is potentially cardio-protective. Recruitment and activation of T cells in the arterial wall is a critical process during atherogenesis, but the effects of lycopene on T-cell response remain to be elucidated. We aimed to determine whether lycopene could modulate T-cell function and activity. Peripheral blood mononuclear cells from 16 healthy adults were cultured in the presence of lycopene-enriched liposomes (0-2.9 μg lycopene/mL) with or without mitogens. Cell cycle as well as the expression of CD69 (marker of early cell activation), CD25 (IL-2 receptor), and CD11a (late activation marker) were measured in T cells, T-helper cells, and T-cytotoxic cells by flow cytometry. IL-2 secretion and cell proliferation were determined by ELISA and [³H]-thymidine incorporation, respectively. Lycopene significantly inhibited lymphocyte proliferation (up to 40%) in activated cells. Lycopene also significantly inhibited CD69 expression (by up to 12%) as well as IL-2 secretion (by up to 29%). However, CD25 and CD11a expression as well as the cell-cycle profile were unaffected by lycopene. Lycopene influences lymphocyte proliferation through its effects on processes involved in early cellular activation, providing one possible mechanism to explain the beneficial effects of tomato-rich diets against cardiovascular disease.